Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc

They present very different kinds of bargains.

2 Stocks That Are Ridiculously Cheap Right Now

BioNTech SE

Pfizer

These stocks are inexpensive yet have solid underlying businesses.

3 Dirt-Cheap Stocks You Can Buy Right Now

Viatris Inc. (NASDAQ:VTRS ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Bill Szablewsk - Head, Global Capital Markets Michael Goettler - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Conference Call Participants Pavan Patel - Bank of America Merrill Lynch Elliot Wilbur - Raymond James Chris Schott - JPMorgan Umer Raffat - Evercore. Greg Fraser - Truist Securities Nate Rich - Goldman Sachs David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Operator Good morning.

Viatris Inc.'s (VTRS) CEO Michael Goettler on Q1 2022 Results - Earnings Call Transcript

Viatris Inc (NASDAQ: VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist.

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

The drugmaker handily beat Wall Street earnings expectations in the first quarter.

Why Viatris Stock Is Popping Today

Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Q1 Earnings Beat Estimates

By selling its only growth asset, Viatris has turned out to be a cigar butt investment that still has many puffs left in it due to its strong free cash flow. Debt remains a concern, but the company continues to deleverage thanks to its strong free cash flow and has accelerated the process through the announced asset sale.

Viatris: A Cigar Butt With Many Puffs Left

PITTSBURGH , May 9, 2022 /PRNewswire/ -- First-Quarter 2022 Results Reflect Strong Operational Start to the Year Total Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2 million Adjusted EBITDA was $1.59 billion U.S. GAAP Net Cash Provided by Operating Activities was $1.14 billion Free Cash Flow was $1.07 billion Achieves Approximately $120 million in New Product Revenue, on Track for 2022 Target of $600 million Confirms Biocon Biologics Transaction on Track for Second Half 2022 Close Announces Board of Directors Declares Quarterly Dividend of Twelve Cents ($0.12) per Share Pays Down Approximately $840 million of Debt, on Track for 2022 Target of Approximately $2 billion, and Maintains Commitment to Investment Grade Rating Viatris Inc. (NASDAQ: VTRS), today reported strong results for the first quarter of 2022. Viatris also announced that its Board of Directors declared a quarterly dividend of twelve cents ($0.12) for each issued and outstanding share of the company's common stock.

Viatris Reports Strong First-Quarter 2022 Results

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Viatris (VTRS) Q1 Earnings Expected to Decline

Hasbro

JPMorgan Chase & Co

Boost your portfolio's balance with these solid, income-generating investments.

Want Extra Income Every Month? Invest in These 3 High-Yielding Dividend Stocks

PITTSBURGH , April 8, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2022 financial results on Monday, May 9, before the open of the U.S. financial markets. Chief Executive Officer  Michael Goettler , President  Rajiv Malik , and Chief Financial Officer  Sanjeev Narula  also will host a webcast at 8:30 a.m.

Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?

Viatris (VTRS) Up 10.2% Since Last Earnings Report: Can It Continue?

New Videos and Resources Support the Social and Emotional Needs of Families Across Generations PITTSBURGH , March 30, 2022 /PRNewswire/ -- Sesame Workshop, the nonprofit behind Sesame Street, is launching new bilingual resources made possible by Viatris Inc. (NASDAQ: VTRS) to support the social and emotional needs of families and caregivers across generations as they collectively continue to adapt to the impacts of the COVID-19 pandemic. Building on previous global resources addressing key emotions felt during the pandemic, launched in 2020, the new phase includes five new videos featuring beloved Sesame characters like Elmo and Grover, as they learn to handle big changes, hold mindful moments, take care of themselves and their loved ones, and so much more.

Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19

Biogen

Viatris Inc (NASDAQ:VTRS) is up 0.5% to trade at $10.94 at last check.

Viatris Subsidiary Wins in Court Against Biogen Patent

Air Products and Chemicals

Scotts Miracle-Gro

The stocks have fallen quite a bit, but analysts look for strong rebounds.

3 Dividend Stocks That Could Soar 34% to 54%, According to Wall Street

Federal Circuit Refuses to Reconsider Decision Invalidating Biogen's Patent Covering its Multiple Sclerosis Product Tecfidera® PITTSBURGH, March 17, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that it is pleased with the decision by the United States Court of Appeals for the Federal Circuit denying Biogen's request that the Court reconsider its prior decision affirming the invalidity of Biogen's U.S. Patent No. 8,399,514, covering Tecfidera®.

Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent

Barclays

Viatris Inc. (VTRS) CEO Mike Goettler Presents at 2022 Barclays Global Healthcare Conference (Transcript)

Approval continues track record of successful firsts in developing complex generic medicines to help increase patient access PITTSBURGH and ST. PAUL, Minn.

Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva

Viatris (VTRS) closed the most recent trading day at $9.96, moving +1.53% from the previous trading session.

Viatris (VTRS) Gains But Lags Market: What You Should Know

Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.

Why is Viatris (VTRS) Stock Down 25% in the Year So Far?

Did the biosimilars deal because they saw business slowing and wanted to create a low cost vertically-integrated player.

Viatris: Takeaways From Management At The Raymond James Conference

The stock crashed after the company reported earnings.

Is Viatris Stock in Trouble?

Viatris Inc. (VTRS) CEO Michael Goettler Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)

Investors were unimpressed with the company's middling fourth-quarter earnings report.

News for Viatris Stock (VTRS)